Lizama BN, Reaver A, Di Caro V, et al. Delineating Mechanisms of Sigma-2 Receptor Modulators in Regulating Retinal Pigment Epithelial Lipid Uptake. Poster presented at ARVO 2025; Salt Lake City, UT
Hamby ME, Lizama BN, Reaver A, et al. Sigma-2 Receptor Modulation Promotes Retinal Pigment Epithelial Cell Survival Following Chronic 7-Ketocholesterol Exposure. Poster presented at ARVO 2025; Salt Lake City, UT
Di Caro V, Cho E, Lizama B, et al. Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Galvin JE, Tolea MI, Iaci JF, et al. SHIMMER: Baseline Data and Early Lessons from the Ongoing Phase 2 Signal-finding Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies (DLB). Poster presented at Clinical Trials on Alzheimer’s Disease (CTAD); Madrid, Spain.
Lizama BN, Reaver A, Cho E, et al. Sigma-2 Receptor Modulators Alter Low-density Lipoprotein Receptor-mediated Lipid Trafficking in Retinal Pigmented Epithelial Cells. Poster presented at 2024 Keystone Conference on Dry Age-related Macular Degeneration; Pacific Grove, CA.
DiCaro V, Lizama BN, Cho E, et al. Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Cho E, Caldwell J, Pandey K, et al. CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Di Caro V, Cho E, Knezovich N, et al. Top-Line CSF Biomarker Outcomes From The Phase 2 Clinical Trial SHINE In Alzheimer’s Patients. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
